TABLE 1.
Characteristics of patients
| Parameter | Value |
|---|---|
| Total no. of patients | 42 |
| Median age, yrs (range) | 46 (18-70) |
| Sex, no. of male patients/no. of female patients | 22/20 |
| Diagnosis, no. (%) of patients | |
| Acute myeloid leukemia | 14 (33.3) |
| Acute lymphoblastic leukemia | 5 (11.9) |
| Chronic myeloid leukemia | 2 (4.8) |
| Primary myelofibrosis | 2 (4.8) |
| Myelodysplastic syndrome | 1 (2.4) |
| Non-Hodgkin's lymphoma | 6 (14.3) |
| Hodgkin's lymphoma | 1 (2.4) |
| Multiple myeloma | 4 (9.5) |
| Chronic lymphocytic leukemia | 3 (7.1) |
| Other | 4 (9.5) |
| CMV serology, no. (%) of patients | |
| D+/R+ | 20 (47.6) |
| D−/R+ | 16 (38.1) |
| D+/R− | 2 (4.8) |
| D−/R− | 4 (9.5) |
| Donor type, no. (%) of patients | |
| HLA-identical sibling | 18 (43.9) |
| Mismatched related donor | 1 (2.4) |
| Matched unrelated donor | 10 (24.4) |
| Mismatched unrelated donor | 12 (29.3) |
| Conditioning regimen, no. (%) of patients | |
| Nonmyeloablative | 27 (64.3) |
| Myeloablative | 15 (35.7) |
| Stem cell source, no. (%) of patients | |
| Peripheral blood | 31 (73,8) |
| Umbilical cord blood | 10 (23.8) |
| Bone marrow | 1 (2.4) |
| GvHDa prophylaxis, no. (%) of patients | |
| Cyclosporine plus methotrexate | 19 (45.2) |
| Cyclosporine plus mycophenolate mofetil | 11 (26.2) |
| Cyclosporine plus prednisone | 10 (23.8) |
| Other | 2 (4.8) |
| Acute GvHD incidence, no. (%) of patients | |
| Grades 0 to I | 24 (57.1) |
| Grades II to IV | 18 (42.9) |
a
GvHD, graft-versus-host disease.